



# BREAST CANCER SCREENING AND DIAGNOSIS

## VARIATION IN GENETIC TESTING RATES AMONG BREAST CANCER PATIENTS AT DIAGNOSIS




There is wide variability in the use of genetic testing at initial breast cancer diagnosis, suggesting potential opportunities to better understand and support testing practices across different settings.

## GENETIC RE-TESTING AT METASTATIC DIAGNOSIS IS INFREQUENTLY PERFORMED



Genetic re-testing at the time of metastatic breast cancer diagnosis appears to be underutilized, with nearly half of oncologists re-testing very few patients, pointing to an opportunity to understand better when and why re-testing is pursued.

## TESTING HER2 ULTRA-LOW NOT YET STANDARDIZED ACROSS PRACTICES



The mixed adoption of ultra-low HER2 testing suggests growing awareness but varied implementation, with many practices either using it selectively or planning to adopt it, and a notable portion of respondents still unaware of its availability or role in breast cancer diagnostics.